DOCSLIB.ORG

Skeletal Muscle Relaxants Review 12/17/2008

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Skeletal Muscle Relaxants Review 12/17/2008 Skeletal Muscle Relaxants Review 12/17/2008 Copyright © 2007 - 2008 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Comments and suggestions may be sent to [email protected]. Skeletal Muscle Relaxant Review FDA-Approved Indications Drug Manufacturer Indications baclofen generic For the alleviation of signs and symptoms of (Lioresal®)1 spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms, concomitant pain, clonus, and muscular rigidity carisoprodol (Soma®)2 generic, Meda As an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated carisoprodol compound or generic with acute, painful musculoskeletal conditions carisoprodol and aspirin3 chlorzoxazone4 generic cyclobenzaprine (Flexeril®)5 generic cyclobenzaprine Victory Pharma (Fexmid®)6 cyclobenzaprine ER (Amrix®)7 Cephalon dantrolene sodium generic For the control of clinical spasticity resulting from (Dantrium®)8* upper motor neuron disorders such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis metaxalone Monarch As an adjunct to rest, physical therapy, and other (Skelaxin®)9 measures for the relief of discomfort associated with acute, painful musculoskeletal conditions methocarbamol (Robaxin®)10 generic As an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions methocarbamol / aspirin11 generic Tetanus orphenadrine citrate12 generic As an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated orphenadrine compound or generic with acute, painful musculoskeletal conditions orphenadrine/aspirin/ caffeine13 tizanidine (Zanaflex®)14 generic, Acorda For the acute and intermittent management of Therapeutics increased muscle tone associated with spasticity • Oral Dantrium is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. © 2007 - 2008 Provider Synergies, L.L.C. Page 1 December 2008 A Coventry Health Care Company All Rights Reserved. Restricted Access – Proprietary and/or Confidential. Do not disseminate or copy without approval. Skeletal Muscle Relaxants Overview Skeletal muscle relaxants are FDA-approved to treat two different types of conditions: muscular pain or spasms from peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes. Both conditions affect patients' mobility and affect independence in activities of daily living and work. Spasticity is a condition in which muscles are continuously contracted causing stiffness or tightness which may interfere with movement and speech. It is usually caused by damage to the portion of the brain or spinal cord that controls voluntary movement. Spasticity can be associated with number of disease entities such as spinal cord injury, multiple sclerosis, traumatic brain injury, cerebral palsy and stroke and is a major health concern. Symptoms may include hypertonicity, clonus, exaggerated deep tendon reflexes, muscle spasms, scissoring and fixed joints. The degree of spasticity varies from mild muscle stiffness to severe, painful, and uncontrollable muscle spasms. Spasticity may cause loss of range of motion, contractures, sleep disorders, and impaired ambulation. Common musculoskeletal conditions associated with muscle spasms include low back pain, neck pain, tension headaches, and myofascial pain syndrome. Hypertonicity and hyperreflexia are not present as with upper motor neuron syndromes. These conditions can cause significant disability and pain. The 2005 Multiple Sclerosis Council for Clinical Practice Guidelines for spasticity management in multiple sclerosis included the oral skeletal muscle relaxant agents baclofen and tizanidine, as effective first-line treatment options.15 Generally, skeletal muscle relaxants are administered orally. Baclofen can be administered intrathecally, and orphenadrine can be administered either intravenously (IV) or intramuscularly (IM). Only the oral agents are included in this review. © 2007 – 2008 Provider Synergies, L.L.C. Page 2 December 2008 A Coventry Health Care Company All Rights Reserved. Restricted Access – Proprietary and/or Confidential. Do not disseminate or copy without approval. Skeletal Muscle Relaxants Pharmacology Drug Mechanism of Action baclofen ♦ Inhibits monosynaptic and polysynaptic reflexes at the spinal level by (Lioresal)16 hyperpolarization of afferent terminals ♦ Additionally acts at supraspinal sites ♦ Has general CNS depressant properties carisoprodol (Soma)17 ♦ In animals, it produces muscle relaxation by blocking interneuronal activity in the descending reticular formation and spinal cord carisoprodol compound ♦ Carisoprodol, in animals, produces muscle relaxation by blocking or interneuronal activity in the descending reticular formation and spinal carisoprodol and cord 18 aspirin ♦ Aspirin is a non-narcotic analgesic with anti-inflammatory activity. Inhibition of prostaglandin biosynthesis appears to account for most of its anti-inflammatory and for at least part of its analgesic properties chlorzoxazone19 ♦ Acts primarily at the spinal cord level and subcortical areas of the brain, inhibiting multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm of varied etiology cyclobenzaprine ♦ Relieves skeletal muscle spasm of local origin without interfering with (Flexeril, Fexmid)20,21 muscle function cyclobenzaprine ER ♦ Ineffective in muscle spasm due to CNS disease (Amrix)22 dantrolene sodium ♦ In isolated nerve-muscle preparation, dantrolene produced relaxation by (Dantrium)23 affecting contractile response of the skeletal muscle at a site beyond the myoneural junction and directly on the muscle itself ♦ In skeletal muscle, dantrolene dissociates the excitation-contraction coupling, probably by interfering with the release of calcium from the sarcoplasmic reticulum ♦ Does not appear to directly affect the CNS; the extent of its indirect effect is unknown metaxalone (Skelaxin)24 ♦ May be caused by general CNS depression methocarbamol ♦ The drug has no direct action on the contractile mechanism of striated (Robaxin)25 muscle, the motor endplate or the nerve fiber methocarbamol / ♦ May be caused by general CNS depression 26 aspirin ♦ Methocarbamol has no direct action on the contractile mechanism of striated muscle, the motor endplate or the nerve fiber ♦ Aspirin is a non-narcotic analgesic with anti-inflammatory activity. Inhibition of prostaglandin biosynthesis appears to account for most of its anti-inflammatory and for at least part of its analgesic properties. orphenadrine citrate27 ♦ Acts centrally at the brain stem ♦ Does not directly relax tense skeletal muscles ♦ Possesses anticholinergic actions orphenadrine compound ♦ Orphenadrine acts centrally at the brain stem or ♦ Orphenadrine does not directly relax tense skeletal muscles orphenadrine/aspirin/ ♦ Orphenadrine possesses anticholinergic actions 28 caffeine ♦ Aspirin is a non-narcotic analgesic with anti-inflammatory activity. Inhibition of prostaglandin biosynthesis appears to account for most of its anti-inflammatory and for at least part of its analgesic properties. ♦ Caffeine increases levels of intracellular cyclic-AMP 29 tizanidine (Zanaflex) ♦ Agonist at alpha2-adrenergic receptor sites ♦ Reduces spasticity by increasing presynaptic inhibition of motor neurons © 2007 – 2008 Provider Synergies, L.L.C. Page 3 December 2008 A Coventry Health Care Company All Rights Reserved. Restricted Access – Proprietary and/or Confidential. Do not disseminate or copy without approval. Skeletal Muscle Relaxants Pharmacokinetics Drug Half-Life (hours) Metabolites Major Route of Elimination baclofen 30 2 - 4 -- kidney (Lioresal) carisoprodol 2 (carisoprodol) 31 Meprobamate liver (Soma) 10 (meprobamate) carisoprodol/ 2 (carisoprodol) meprobamate aspirin (Soma kidney
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Taking Muscle Relaxers Long Term
    Taking Muscle Relaxers Long Term Teeny and saltant Yankee sortes while inappreciable Gabriell razzes her curtailment apace and redeploy argumentatively. Interior-sprung Laurence hoarsens no electrodes quarrelled inscrutably after Puff participate currently, quite quick-witted. Scot gibbers untimely if step-up Torry palavers or overdid. Why you think properly and are already have been associated with multiple sclerosis, or cdc or glycerol injection. Neck pain is a muscle spasms or other muscle relaxers are taking a supervised detox. Signs of a Cyclobenzaprine Overdose? NSAIDs and acetaminophen in high doses, or if god for making long both, can cause serious side effects. Down Arrow keys to bloat or in volume. The serious risks associated with long-term NSAID benzodiazepine. Com is there a subsidiary of flexeril abuse was generally prescribed mainly because we may help manage your liver or trigger points on your doctor? Greenhouse treatment at risk when this medicine, if a long term. Muscle relaxants used at random have been shown to relieve immediate pain. Will i need something that she previously worked as long term treatment provider a long term rehab better if they work. They may have shown one is comprised of visits, dr leonard said, take it in the aim of? Pomona, NY: Barr Laboratories. Then research demonstrated that prolonged bedrest was use a bad repair It he no better and what worse than taking it secret for hour day his two. Flexeril without a prescription or using it in a manner utilize it is something intended example be used. Long-term Flexeril use can sure to withdrawal symptoms Learn better about the symptoms and surpass to safely quit taking study drug.
    [Show full text]
  • A Randomized, Placebo Controlled Trial of Ibuprofen + Metaxalone, Tizanidine, Or Baclofen for Acute Low Back Pain
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Ann Emerg Manuscript Author Med. Author Manuscript Author manuscript; available in PMC 2020 October 01. Published in final edited form as: Ann Emerg Med. 2019 October ; 74(4): 512–520. doi:10.1016/j.annemergmed.2019.02.017. A randomized, placebo controlled trial of ibuprofen + metaxalone, tizanidine, or baclofen for acute low back pain Benjamin W. Friedman, MD MS1, Eddie Irizarry, MD1, Clemencia Solorzano, PharmD2, Eleftheria Zias, RPh2, Scott Pearlman, MD1, Andrew Wollowitz, MD1, Michael P. Jones, MD1, Purvi D. Shah, MD MSc1, E. John Gallagher, MD1 1Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore, Bronx, NY, USA 2Pharmacy Department, Montefiore, Bronx, NY, USA Abstract Background: Patients with low back pain (LBP) are often treated with non-steroidal antiinflammatory drugs (NSAID) and skeletal muscle relaxants (SMR). We compared functional outcomes and pain among acute LBP patients randomized to a one week course of ibuprofen + placebo versus ibuprofen + one of three SMRs: baclofen, metaxalone, or tizanidine. Methods: This was a randomized, double-blind, parallel group, 4-arm study conducted in two urban emergency departments (ED). Patients with non-radicular LBP for <=two weeks were eligible if they had a score >5 on the Roland-Morris Disability Questionnaire (RMDQ), a 24-item inventory of functional impairment due to LBP. All participants received 21 tablets of ibuprofen 600mg, to be taken TID, as needed. Additionally, they were randomized to baclofen 10mg, metaxalone 400mg, tizanidine 2mg, or placebo. Participants were instructed to take one or two of these capsules, TID, as needed. All participants received a 10 minute educational session.
    [Show full text]
  • Ibuprofen Plus Metaxolone, Tizandine, Or Baclofen for Low Back Pain. a Randomized Trial
    IRB NUMBER: 2017-7566 IRB APPROVAL DATE: 03/29/2017 Ibuprofen plus metaxolone, tizandine, or baclofen for low back pain. A randomized trial Ibuprofen plus metaxolone, tizanidine, or baclofen for LBP. A randomized trial Version 1 03272017 IRB NUMBER: 2017-7566 IRB APPROVAL DATE: 03/29/2017 Specific Aims Up to ½ of emergency department (ED) patients with acute, new onset low back pain (LBP) report persistent moderate or severe pain one week after the ED visit.(1, 2) Skeletal muscle relaxants (SMR) are commonly used to treat LBP though evidence supporting efficacy is generally lower quality. We have demonstrated previously that two commonly used SMRs, cyclobenzaprine(1) and diazepam(2), when combined with an NSAID, do not improve LBP outcomes more than NSAIDs used alone. This proposal seeks to determine whether there is any benefit from other commonly used SMRs. The first SMR to be included in this study is baclofen. The precise mechanism of action of baclofen is unknown. Baclofen inhibits monosynaptic and polysynaptic reflexes at the spinal level, although actions at supraspinal sites may contribute to its clinical effect. Baclofen is an analog of the neurotransmitter GABA, but it is uncertain whether GABA is involved in its clinical effects. In a randomized, placebo controlled study, 200 patients with acute LBP were randomized to baclofen or placebo.(3) Patients randomized to baclofen reported modestly better outcomes four and ten days later. The second investigational SMR is tizanidine. Tizanidine is a centrally acting alpha-2-adrenergic agonist. It reduces muscle spasticity by increasing presynaptic inhibition of motor neurons. In a randomized, placebo controlled trial, 112 patients with acute LBP were randomized to tizanidine.
    [Show full text]
  • Case Report Carbamazepine Toxicity Following Oxybutynin And
    Spinal Cord (2005) 43, 252–255 & 2005 International Spinal Cord Society All rights reserved 1362-4393/05 $30.00 www.nature.com/sc Case Report Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report T Vander*,1, H Odi1, V Bluvstein1, J Ronen1,2 and A Catz1,2 1Department of Spinal Rehabilitation, Loewenstein Rehabilitation Hospital, Raanana, Israel; 2Tel-Aviv University, Tel-Aviv, Israel Objective: To report a case of Carbamazepine toxicity following the administration of Oxybutynin and Dantrolene. Study design: A case report. Setting: The Spinal Rehabilitation Department, Loewenstein Hospital, Raanana, Israel. Methods: A patient with C6D tetraplegia who sustained intoxication because of drug interaction is presented. She had been treated by Carbamazepine 1000 mg/day for neuropathic pain for 2 years without clinical or laboratory signs of toxicity. After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of Carbamazepine intoxication. Trying to adjust the treatment to the patient’s requirements, Carbamazepine together with Oxybutynin and Dantrolene was readministrated in lower doses. Results: The combination of these drugs, even small doses, caused toxicity. Adding Dantrolene and Oxybutynin elevated the blood level of Carbamazepine, possibly by inhibition of cytochrome P450. Conclusion: A possible pharmacokinetic interaction between Dantrolene and Oxybutynin should be borne in mind when considering Carbamazepine medication for a patient with a spinal cord lesion. Spinal Cord (2005) 43, 252–255. doi:10.1038/sj.sc.3101689; Published online 1 February 2005 Keywords: Carbamazepine; Oxybutynin; Dantrolene; drug interaction; cytochrome P450 Introduction Both Oxybutynin chloride and Dantrolene sodium are be required when patients have concomitant post- widely used in patients with spinal cord lesion (SCL).
    [Show full text]
  • SKELAXIN® (Metaxalone) Tablets
    SKELAXIN® (Metaxalone) Tablets SKELAXIN TABLET DESCRIPTION ® SKELAXIN (metaxalone) is available as an 800 mg oval, scored pink tablet. Chemically, metaxalone is 5-[(3,5- dimethylphenoxy) methyl]-2-oxazolidinone. The empirical formula is C12H15NO3, which corresponds to a molecular weight of 221.25. The structural formula is: Metaxalone is a white to almost white, odorless crystalline powder freely soluble in chloroform, soluble in methanol and in 96% ethanol, but practically insoluble in ether or water. Each tablet contains 800 mg metaxalone and the following inactive ingredients: alginic acid, ammonium calcium alginate, B-Rose Liquid, corn starch, and magnesium stearate. CLINICAL PHARMACOLOGY Mechanism of Action The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system (CNS) depression. Metaxalone has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber. Pharmacokinetics The pharmacokinetics of metaxalone have been evaluated in healthy adult volunteers after single dose administration of SKELAXIN under fasted and fed conditions at doses ranging from 400 mg to 800 mg. Absorption Peak plasma concentrations of metaxalone occur approximately 3 hours after a 400 mg oral dose under fasted conditions. Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours. Doubling the dose of SKELAXIN from 400 mg to 800 mg Reference ID: 4230551 results in a roughly proportional increase in metaxalone exposure as indicated by peak plasma concentrations (Cmax) and area under the curve (AUC). Dose proportionality at doses above 800 mg has not been studied.
    [Show full text]
  • Medication Alert
    Trade Name Generic Name Manufacturer Akineton Biperiden Knoll Muscle relaxing Analexin Phenyramidol Salicylate Neisler medications Anectine Succinycholine Chloride B.W. & Co. patients with Bancaps Acetaminophin, Mephenesin Butabarbital Sodium West Myasthenia Gravis Deprol Meprobamate & Benscyyzine Wallace should avoid. Dioloxl Mephensein Camrick Disipal Orphenadrine Hydrochloride Riker Norman A. David, MD, University of Oregon Medical Equagesic Meprobamate & Ethobeptazine Wyeth School Pharmacology Equanitrate Meproamate & Pentserythritol Wyeth Department Equanil Meprobamate Wyeth Flaxedil Has Curare Effect, Galiamine, Triethiodide Camrick Halabar Mephenesin & Butabarbital Camrick Kemadrin Procycllidine Hydrocholoride B.W. & Co. Maolate Chlorphenesin Carbamate Upjohn Meprospan Meprobamate Wallace Medigesic Mephenesin Medics Metubine Dimethyl Tubocurzine Loside Lilly Milpath Meprobamate Wallace Milprem Meprobamate + Conjugated Estrogens Wallace Miltown Meprobamate Wallace Miltrate Meprobamate + Pentserythritol Wallace Mylaxen Hexafluroenium Bromide – Cholinesterase Inhibitor Neisler Norflax Orphenadrine Citrate Riker Norgesic Orphenadrine + Aspirin + Phenacetin Riker Parglex Chlorzoxazone McNeil Parafon Forte Chlorzoxazone & Acetaminophen McNeil Phenoxene Chlorzoxazone Hydrochloride Pitman-Moore Quelicin Succinylcholine Abbott Quinine Several Different Salts Lilly Rela Carisoprodol Schering Robaxin Methocarbamal + Aspirin A.H. Robins Robaxisal Methocarbamal + Phenephen A.H. Robins Sinaxar Stramate Armor Skelaxin Metaxalone A.H. Robins Soma
    [Show full text]
  • Serotonin Syndrome Associated with Metaxalone and Venlafaxine Shreemayee De DO Lehigh Valley Health Network, [email protected]
    Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Serotonin Syndrome Associated with Metaxalone and Venlafaxine Shreemayee De DO Lehigh Valley Health Network, [email protected] Michael Kalil DO Lehigh Valley Health Network, [email protected] Follow this and additional works at: http://scholarlyworks.lvhn.org/medicine Part of the Medical Sciences Commons Published In/Presented At De, S., & Kalil, M. (2016, April 26). Serotonin Syndrome Associated with Metaxalone and Venlafaxine. Poster presented at LVHN Department of Medicine Research Day, Lehigh Valley Health Network, Allentown, PA. This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact [email protected]. Serotonin Syndrome Associated with Metaxalone and Venlafaxine Shreemayee De, DO and Michael Kalil, DO Department of Medicine, Lehigh Valley Health Network, Allentown, PA Abstract Case Presentation Discussion Introduction: Metaxalone is a commonly prescribed muscle relaxant. However, due to its proposed Patient: 65-year-old male with history of cryptogenic cirrhosis had back pain • SS occurs when there is increased amount of serotonin neurotransmitters at synapses. SSRI drugs such as venlafaxine function by inhibiting reuptake of serotonin back into the mechanism of action as a weak monoamine oxidase inhibitor, it can interact with drugs with serotonergic resulting from a fall a week prior to his admission. Three days after his fall the patient presynaptic neurons. activity instigating a potentially deadly set of symptoms identified as serotonin syndrome. was prescribed with metaxalone 800 mg and was advised to take ½ to 1 tablet every 8 • Metaxalone has been correlated to SS, especially when given in addition to drugs with serotonergic activity.
    [Show full text]
  • Drug Class Review on Skeletal Muscle Relaxants
    Drug Class Review on Skeletal Muscle Relaxants Final Report Update 2 May 2005 Original Report Date: April 2003 Update 1 Report Date: January 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2005 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically (see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 2 Drug Effectiveness Review Project TABLE OF CONTENTS Introduction........................................................................................................................4 Scope and
    [Show full text]
  • Acetaminophen and Methocarbamol
    PATIENT & CAREGIVER EDUCATION Acetaminophen and Methocarbamol This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: Canada Muscle & Back Pain Relief [OTC]; Robaxacet [OTC] Warning Liver problems have happened with the use of acetaminophen. Sometimes, this has led to a liver transplant or death. Most of the time, liver problems happened in people taking more than 4,000 mg (milligrams) of acetaminophen in a day. People were also often taking more than 1 drug that had acetaminophen in it. If you have questions, talk with your doctor. What is this drug used for? It is used to ease pain. It is used to relax muscles. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have liver disease. Acetaminophen and Methocarbamol 1/7 If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson’s disease like selegiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. If you are taking any of these drugs: Linezolid or methylene blue. If you are taking another drug that has the same drug in it. This is not a list of all drugs or health problems that interact with this drug.
    [Show full text]
  • Medicaid Drug Use Criteria
    Medicaid Drug Use Criteria Skeletal Muscle Relaxants ● Developed October 2008. ● Revised June 2020; May 2018; May 2016; September 2014; December 2012; March 2011. Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information contained is for the convenience of the public. The Texas Health and Human Services Commission is not responsible for any errors in transmission or any errors or omissions in the document. Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Vendor Drug Program formulary coverage. Prepared by: ● Drug Information Service, UT Health San Antonio ● The College of Pharmacy, the University of Texas at Austin 1 Dosage 1.1 Adults The skeletal muscle relaxants (SMRs), carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol, metaxalone, and orphenadrine, are FDA- approved for short-term use to manage discomfort associated with acute, painful musculoskeletal conditions such as strains, sprains, and other muscle injuries. These agents should be used as an adjunct to non-pharmacologic treatments, 1 including rest and physical therapy. The SMRs, baclofen, dantrolene, and tizanidine are FDA-approved for managing spasticity due to upper motor neuron disorders (e.g., spinal cord injury, cerebral palsy, multiple sclerosis, stroke). Maximum recommended dosages for SMRs are summarized in Table 1. Dosages exceeding these recommendations
    [Show full text]
  • Medicines Optimisation Programme Board (MOPB)
    Medicines Optimisation Programme Board (MOPB) Drug Methocarbamol Brands Robaxin® Decision West Essex CCG does not recommend Methocarbamol as a short-term adjunct to the symptomatic treatment of acute musculoskeletal disorders associated with painful muscle spasms for prescribing in Primary or Secondary Care. Date 25/07/2019 Evidence The BNF states Methocarbamol is “Less suitable for prescribing” which applies to preparations that are considered by the Joint Formulary Committee to be less suitable for prescribing.1 Methocarbamol is licensed as a short-term adjunct to the symptomatic treatment of acute musculoskeletal disorders associated with painful muscle spasms. The usual dose in adults is 2 tablets four times daily, but therapeutic response has been achieved with doses as low as 1 tablet three times daily.2 However, Clinical Knowledge Summaries do not list it as a treatment option for muscle spasm in low back pain, and it is not mentioned in NICE guidelines NG59 Low back pain and sciatica in over 16s: assessment and management. Methocarbamol’s efficacy in other musculoskeletal conditions has not been investigated in rigorous RCTs. Side effects include anxiety, confusion, drowsiness, dizziness, memory loss, seizures, headache, fever, and nausea. NICE CKS Back Pain- low (without radiculopathy) Nov 2018 If the person has muscle spasm, consider offering a short course of a benzodiazepine, such as diazepam 2 mg up to three times a day for up to 5 days, if not contraindicated. Offering benzodiazepines for muscle spasm The recommendation to consider offering a benzodiazepine such as diazepam if there is muscle spasm is based on expert opinion in the US clinical guideline Adult acute and subacute low back pain published by the Institute for Clinical Systems Improvement [ICSI, 2012], which notes that historically muscle relaxants have been recommended on the basis of evidence from trials on the management of non-specific low back pain (without radiculopathy).
    [Show full text]